CG Oncology | 8-K:重大事件
CG Oncology | 4:持股变动声明-高管 Patterson Joshua F.
CG Oncology | 3:首次持股声明-高管 Patterson Joshua F.
CG Oncology | 8-K:CG Oncology公布2024年第一季度财务业绩并提供业务最新情况
CG Oncology | 10-Q:季度报表
CG Oncology | 8-K:重大事件
CG Oncology | SC 13G/A:超过5%持股股东披露文件(修正)-Xiangmin Cui(8.2%),Decheng Capital Global Life Sciences Fund IV, L.P.(7.4%)等
CG Oncology | 4/A:持股变动声明(修正)-股东 Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology | 10-K:年度报表
CG Oncology | SC 13G:超过5%持股股东披露文件-Kissei Pharmaceutical Co., Ltd.(5.3%)
CG Oncology | 8-K:重大事件
CG Oncology | SC 13G:超过5%持股股东披露文件-TCG Crossover GP I, LLC(5.4%),TCG Crossover Fund I, L.P.(5.4%)等
CG Oncology | SC 13G:超过5%持股股东披露文件-Xiangmin Cui(7.6%),Decheng Capital Global Life Sciences Fund IV, L.P.(6.9%)等
CG Oncology | SC 13G:超过5%持股股东披露文件-Patrick G. Enright(7.0%),Juliet Tammenoms Bakker(7.0%)等
CG Oncology | SC 13G:超过5%持股股东披露文件-James Tananbaum (“Tananbaum”)(5.7%),Foresite Capital Fund VI, L.P. (“FCF VI”)(3.2%)等
CG Oncology | 4:持股变动声明-高管 Kasturi Vijay
CG Oncology | 4:持股变动声明-高管 Roche Corleen M.
CG Oncology | 4:持股变动声明-董事 Song Hong Fang
CG Oncology | 4:持股变动声明-股东 Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology | 8-K:重大事件
暂无数据